ω-3 fatty acid treatment in cardiac syndrome X: a double-blind, randomized, placebo-controlled clinical study
Evin Bozcali, Erhan Babalik, Solen Himmetoglu, Ismail Mihmanli, Sadik Toprak
article (Uluslararası, Hakemli) | Yazar(lar): Evin Bozcali, Erhan Babalik, Solen Himmetoglu, Ismail Mihmanli, Sadik Toprak | Yıl: 2013 | Dergi/Kurum: CORONARY ARTERY DISEASE | İndeks: WOS.SCI | DOI: 10.1097/mca.0b013e32835f3005 | Anahtar Kelimeler: coronary resistance, endothelial dysfunction, lipid peroxidation, micro
Objective We conducted a clinical trial to examine the effect of omega-3 fatty acids in patients with cardiac syndrome X (CSX). We aimed to evaluate the potential impact of omega-3 fatty acids on endothelial function, oxidative stress, and symptom relief in the CSX.
Methods and results Eighteen patients with CSX were enrolled according to a double-blind, randomized, placebo-controlled design. Patients were randomized to omega-3 fatty acids (1440 mg/day, n = 8) or placebo (n = 10) for 4 months. We assessed plasma levels of malondialdehyde (MDA), endothelium-dependent vasodilatation [flow-mediated dilatation (FMD)], endothelium-independent vasodilatation [nitroglycerin-mediated dilatation (NMD)], and status of symptom [score with Seattle Angina Questionnaire (SAQ)] before and after the treatment. After 4 months, patients who were treated with omega-3 fatty acids showed significant increases in the FMD (from 47 +/- 48 to 104 +/- 23%, P<0.05) and NMD (from 51 +/- 53 to 93 +/- 35%, P<0.05) values, and significant decreases in the plasma MDA levels (4.4 +/- 0.86 to 3.35 +/- 0.33 mu mol/l, P = 0.012). SAQ scores were increased significantly in both groups (from 60 +/- 14 to 73 +/- 15%, P<0.05 placebo, from 67 +/- 0 to 81 +/- 9%, P<0.05 treatment group). NMD was correlated negatively with the plasma MDA levels.
Conclusion Four months of therapy with a moderate dose of omega-3 fatty acids improved the endothelial function and reduced oxidative stress in patients with CSX. Coron Artery Dis 24:328-333 (c) 2013 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.